Showing 901-910 of 1148 results for "".
- Bound by Bureaucracy: How Medicare Part D is Tying the Hands of Neurologistshttps://practicalneurology.com/columns/practice-management/bound-by-bureaucracy-how-medicare-part-d-is-tying-the-hands-of-neurologists/31330/Medicare Part D: Challenges and Implications for Neurological PracticeThe rollout of Medicare Part D has significantly impacted neurological practices, revealing numerous challenges that healthcare professionals continue to navigate. Initially intended to provide elderly patients with more prescript
Chronic Facial Weakness and Deafness
https://practicalneurology.com/diseases-diagnoses/stroke/chronic-facial-weakness-and-deafness/31104/A 66-year-old Indian man reported bilateral facial weakness that started when he was 15 to 20 years old and affected both upper and lower parts of the face. Two to three years later, he developed hoarseness and was found to have bilateral vocal cord paralysis, which required a tracheostomy several y- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31280/Effective financial management is crucial for the sustainability and growth of medical practices. In the August 2006 issue of Practical Neurology, Craig T. Williams emphasizes the significance of establishing a comprehensive budget as the financial roadmap for a medical practice. This budget outline
- Letters to the Editor: The tPA Debate Continues: “Dr. Anonymous” Respondshttps://practicalneurology.com/columns/practice-management/letters-to-the-editor-the-tpa-debate-continues-dr-anonymous-responds/31488/Ongoing Debate on tPA Use in Acute Stroke ManagementAn anonymous physician from Oklahoma responds to prior discussions on the use of tissue plasminogen activator (tPA) in acute stroke treatment, emphasizing a cautious approach grounded in ethical and practical considerations. The physician clarifies
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0507Dementia-pdf/31172/Progranulin Emerges as a Key Player in Frontotemporal Dementia ResearchIn the evolving landscape of neurodegenerative disease research, progranulin has rapidly ascended to prominence, akin to a breakout star in a high-stakes competition. Progranulin, a 593 amino acid glycoprotein, has been identifie
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/PN0706epilepsy-pdf/31294/Electrodiagnostic tools, particularly electroencephalography (EEG), play a crucial role in the diagnosis and management of epilepsy, complementing medical treatment strategies. EEG is widely used to narrow differential diagnoses and support clinical suspicions of seizure disorders. Video-EEG, which
- Protecting Stroke Patients from Seizureshttps://practicalneurology.com/diseases-diagnoses/stroke/pn0407-post-stroke-pdf/31194/Post-Stroke Seizures: Epidemiology, Classification, and ManagementAs the global population ages, the incidence of post-stroke seizures is expected to rise, highlighting their clinical significance in neurology. Stroke markedly increases the risk of seizures, with a 23- to 35-fold higher incidence co
- Reimbursement: Chart a Course for Successhttps://practicalneurology.com/columns/practice-management/reimbursement-chart-a-course-for-success/31432/Effective documentation and coding are critical yet challenging aspects of neurology practice, significantly impacting insurance reimbursements. Neurologists often face delays and uncertainties in payments due to the complex and stringent requirements of third-party payers. A single coding error can
- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/30976/Combination Therapy in Alzheimer’s Disease: Long-Term Safety and EfficacyRecent advancements in Alzheimer's disease (AD) treatment highlight the potential benefits of combination therapy using cholinesterase inhibitors (CIs) and memantine (MEM). A pivotal study conducted by Dr. Alireza Atri and coll
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0608Dementia-pdf/31012/Current Alzheimer’s disease (AD) research predominantly targets the reduction and elimination of beta-amyloid 42 and phosphorylated Tau proteins, aiming to develop disease-modifying treatments. These pathological markers are critical in the onset and progression of AD, and intervening in their pathw